Anthropic has formally warned investors that its technology may pose “existential risks to humanity” in a long-awaited initial public offering prospectus circulated with a small group of partners in recent days.

Anthropic plans to caution potential investors in its IPO that advanced AI could pose "catastrophic or existential risks to humanity", an extraordinary warning by a company seeking to profit from the same technology.

This is the real conversation. CRISPR is one of the biggest scientific discoveries in modern history, and its ability to rewrite DNA has a ton of potentially viable uses in medical science. So, finding something like CRISPR, as Anthropic did, is definitely going to warrant some discussion.

By Echo Wang Sept 28 (Reuters) - Anthropic is making a massive bet that AI will transform the global economy more profoundly than industrialization, electricity and the internet, according to its IPO prospectus seen by Reuters.

Anthropic's filing said one of its core advantages is that it has "a culture that promotes a low-ego, truth-seeking environment, where frontier AI capability and safety are mutually reinforcing."

The Claude maker dedicated roughly 80 of 261 prospectus pages to risk factors, more than the 48 pages it used to describe its business

At this point, Anthropic looks like the most important of the trio of big IPOs that includes SpaceX and OpenAI. Unlike SpaceX, it is singularly focused on AI and is at the frontier of model development. It's now bigger than rival OpenAI. It's growing faster, and it's profitable, while OpenAI is still losing billions each quarter.

A look at Anthropic's early IPO prospectus by Reuters highlighted some of the now well-documented risks associated with the company's frontier AI models. Anthropic warns that

Anthropic says the new mid-tier model is a clear upgrade over Sonnet 5 and costs up to 30 percent less per task.

Beam's last major update on their pipeline came on September 10th, at the Cantor Fitzgerald Global Healthcare Conference. CEO John Evans noted progress for BEAM-302, its 'potentially best- and first-in-class therapy designed to directly correct the root cause of AATD and address both liver and lung manifestations of disease'.

That’s according to a leaked IPO filing seen by Reuters, with $8.06 billion specifically highlighted in operating losses for 2025, more than double the $2.98 billion it reported in 2024. The AI startup spent $7.